Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0FNHGM |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Hu67 |
|||||
| Organization | JIANGSU HENGRUI MEDICINE CO., LTD. |
|||||
| Synonyms |
Hu67
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Varible Domain |
EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYHMNWVKQMPGKGLEWMGDINPDIGGTSY
NQNFKGKVTISVDKSISTAYLQWSSLKASDTAMYYCARWDFDSFANWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQMTQSPSSLSASVGDRVTITCRASESVSIIGTNLIHWYQQKPGKAPKLLIYHASNLET
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQSRKIPYTFGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Hu67-14-2-A (1) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.331 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9.236 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
71.83 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
Hu67-14-2-A (2) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9.388 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
15.58 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
71.95 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.58 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||